4//SEC Filing
METABASIS THERAPEUTICS INC 4
Accession 0001209191-10-005456
CIK 0001053221operating
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 12:46 PM ET
Size
6.2 KB
Accession
0001209191-10-005456
Insider Transaction Report
Form 4
EVNIN LUKE
Director10% Owner
Transactions
- Disposition to Issuer
Common Stock
2010-01-27−4,814,725→ 0 total(indirect: See footnote)
Footnotes (2)
- [F1]Disposed of pursuant to the merger agreement among Ligand Pharmaceuticals Incorporated ("Ligand"); Moonstone Acquisition, Inc., a wholly-owned Subsidiary of Ligand and Metabasis Therapeutics, Inc. dated October 26, 2009 and as amended on November 25, 2009 (the "Merger Agreement") in exchange for $0.045741 per share in cash, without interest, plus one Roche CVR, one TR Beta CVR, one Glucagon CVR and one General CVR, which rights are subject to the terms and conditions of the respective CVR Agreements, as described in the Merger Agreement.
- [F2]The shares were held as follows: 3,241,318 by MPM BioVentures II-QP, L.P. ("BV II QP"), 357,666 by MPM BioVentures II, L.P. ("BV II"), 74,628 by MPM Asset Management Investors 2000B LLC ("AM 2000") and 1,141,113 by MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG ("BV KG"). MPM Asset Management II, L.P. and MPM Asset Management II LLC ("AM II LLC") are the direct and indirect general partners of BV II QP, BV II and BV KG. The reporting person is a member of AM II LLC and AM 2000. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Documents
Issuer
METABASIS THERAPEUTICS INC
CIK 0001053221
Entity typeoperating
Related Parties
1- filerCIK 0001053221
Filing Metadata
- Form type
- 4
- Filed
- Jan 28, 7:00 PM ET
- Accepted
- Jan 29, 12:46 PM ET
- Size
- 6.2 KB